文献速递血脂与心血管预防冠心病

脂蛋白(a)与LPA遗传风险评分在动脉粥样硬化性心血管疾病风险预测中的临床效用

Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease.
PubMed 文献 · JAMA Cardiol · 2021-01-01

中位随访11.1年,两者均与ASCVD独立相关,但GRS的关联在调整实测脂蛋白(a)后明显减弱;在临界至中等风险人群中,加入实测脂蛋白(a)或GRS对QRISK3模型的风险区分度改善有限。

要点

  • LPA GRS可解释 White/European 个体实测脂蛋白(a)约60%的变异。
  • 实测脂蛋白(a)与LPA GRS均独立关联ASCVD,但GRS关联在调整脂蛋白(a)后显著减弱。
  • 在临界至中等风险人群中,加入脂蛋白(a)或GRS对QRISK3区分度改善有限。

核心结论

  • 在需要时,中年人群的心血管风险评估可采用直接测量脂蛋白(a)或LPA遗传风险评分。

研究设计与样本

  • 使用外部推导权重计算LPA基因43个变异构成的遗传风险评分,随访中位11.1年。

主要发现

  • LPA GRS可解释 White/European 个体实测脂蛋白(a)约60%的变异。
  • 实测脂蛋白(a)每增加120 nmol/L与ASCVD复合终点的风险比为1.26(95% CI 1.23-1.28),LPA GRS的风险比为1.29(95% CI 1.26-1.33),P < .001。
  • 调整实测脂蛋白(a)后,LPA GRS与ASCVD的关联显著减弱。
  • 在临界至中等风险人群中,加入实测脂蛋白(a)或LPA GRS对QRISK3的AUC改善分别为0.640(95% CI 0.633-0.647) vs 0.642(95% CI 0.635-0.649),P = .005和P = .01。

临床怎么用

  • 中年人群进行心血管风险评估时,若需评估脂蛋白(a)相关风险,可考虑直接测量脂蛋白(a)或使用LPA遗传风险评分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Lipoprotein(a) is a highly heritable biomarker independently associated with atherosclerotic cardiovascular disease (ASCVD). It is unclear whether measured lipoprotein(a) or genetic factors associated with lipoprotein(a) can provide comparable or additional prognostic information for primary prevention. OBJECTIVE: To determine whether a genetic risk score (GRS) comprising 43 variants at the LPA gene, which encodes apolipoprotein(a), has clinical utility in assessing ASCVD risk compared with and in addition to lipoprotein(a) measurement. DESIGN, SETTING, AND PARTICIPANTS: The UK Biobank is a prospective observational study of approximately 500 000 volunteers aged 40 to 69 years who were recruited from 22 sites across the United Kingdom between 2006 and 2010. Using externally derived weights, an LPA GRS was calculated for 374 099 unrelated individuals with array-derived genotypes and lipoprotein(a) measures. Data were analyzed from April 2020 to March 2020. EXPOSURES: Measured lipoprotein(a) and LPA GRS. MAIN OUTCOMES AND MEASURES: We estimated the associations between measured lipoprotein(a) and LPA GRS with the incidence of ASCVD (peripheral arterial disease, coronary artery disease, myocardial infarction, ischemic stroke, and cardiovascular mortality) using Cox proportional hazards models. To determine the utility of using measured lipoprotein(a) and LPA GRS as risk enhancers for ASCVD, we assessed the potential improvement in ASCVD risk discrimination by QRISK3 and Pooled Cohort Equations among individuals with borderline to intermediate risk (n = 113 703 and 144 350, respectively). RESULTS: The mean age of the overall study population was 57.6 years, and 204 355 individuals were female (54.6%). During a median follow-up of 11.1 years (interquartile range, 1.4 years), 15 444 individuals developed an incident ASCVD event (5.1%). The LPA GRS explained approximately 60% of the variation in measured lipoprotein(a) for White/European individuals. Independently, both lipoprotein(a) and LPA GRS were associated with incident, composite ASCVD (hazard ratio per 120 nmol/L increase, 1.26; 95% CI, 1.23-1.28 vs hazard ratio, 1.29; 95% CI, 1.26-1.33; P < .001). The association between LPA GRS and ASCVD was substantially attenuated after adjusting for measured lipoprotein(a). Adding measured lipoprotein(a) or LPA GRS to QRISK3 provided modest improvements to the risk discrimination of incident ASCVD events (area under the receiver operating curve, 0.640; 95% CI, 0.633-0.647 vs 0.642; 95% CI, 0.635-0.649 for both; P = .005 and P = .01, respectively). CONCLUSIONS AND RELEVANCE: When indicated, cardiovascular risk assessment with lipoprotein(a) at middle-age may include direct measurement or an LPA GRS.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Trinder M, Uddin MM, Finneran P, et al. Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021. PMID: 33021622. doi:10.1001/jamacardio.2020.5398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。